Lisocabtagene maraleucel对比标准二线治疗(挽救化疗后自体干细胞移植)用于复发或难治性大B细胞淋巴瘤:TRANSFORM三期试验中期分析
TRANSFORM是一项全球三期试验,纳入47个中心、原发难治或12个月内早期复发的LBCL成人患者(18-75岁、ECOG≤1、PET阳性、适合自体HSCT),1:1随机接受liso-cel(100×10^6 CAR+ T细胞静脉输注)或标准治疗(R-DHAP/R-ICE/R-GDP三周期挽救化疗后对缓解者行自体HSCT)。中期分析时中位随访6.2个月,liso-cel组中位EFS为10.1个月(95%CI 6.1-未达到),标准治疗组为2.3个月(95%CI 2.2-4.3),分层HR 0.35(95%CI 0.23-0.53),单侧p<0.0001。liso-cel组3级及以上中性粒细胞减少80%、长时间细胞减少43%,标准治疗组分别为51%、3%;liso-cel组3级CRS 1%、3级神经事件4%。作者认为结果支持liso-cel作为早期复发或难治性LBCL新的二线治疗推荐。
要点
- TRANSFORM中期分析显示,liso-cel组中位EFS 10.1个月(95%CI 6.1-未达到),优于标准治疗组的2.3个月(95%CI 2.2-4.3),分层HR 0.35(95%CI 0.23-0.53),单侧p<0.0001。
- liso-cel组3级及以上中性粒细胞减少80%(74/92)、长时间细胞减少43%(40/92),标准治疗组分别为51%(46/91)、3%(3/91);两组贫血均为49%(45/92 vs 45/91),血小板减少分别为49% vs 64%。
- liso-cel组3级CRS 1%(1/92)、3级神经事件4%(4/92),无4级或5级事件;标准治疗组1例治疗相关死亡(脓毒症),liso-cel组无治疗相关死亡。
- 作者认为结果支持liso-cel作为早期复发或难治性LBCL新的二线治疗推荐。
适用人群与场景
- 18-75岁成人,原发难治或早期复发(对初始治疗有反应后≤12个月内复发)的大B细胞淋巴瘤患者。
- ECOG体能状态评分≤1、器官功能充足、符合Lugano 2014标准PET阳性病灶、适合自体HSCT的候选者。
诊断标准与关键阈值
- 疾病状态:原发难治或早期复发(对初始治疗有反应后≤12个月内复发)。
- PET阳性病灶依据Lugano 2014标准。
- ECOG体能状态评分≤1。
处置流程与药物剂量
- liso-cel组:liso-cel 100×10^6 CAR+ T细胞静脉输注,作为二线治疗。
- 标准治疗组:3周期挽救免疫化疗静脉给药,方案为R-DHAP(利妥昔单抗375 mg/m2第1天;地塞米松40 mg第1-4天;阿糖胞苷2000 mg/m2第2天两次输注;顺铂100 mg/m2第1天)、R-ICE(利妥昔单抗375 mg/m2第1天;异环磷酰胺5000 mg/m2第2天;依托泊苷100 mg/m2第1-3天;卡铂AUC 5[最大剂量800 mg]第2天)或R-GDP(利妥昔单抗375 mg/m2第1天;地塞米松40 mg第1-4天;吉西他滨1000 mg/m2第1、8天;顺铂75 mg/m2第1天),缓解者随后接受大剂量化疗和自体HSCT。
红旗征与不能漏的情况
- liso-cel组3级CRS发生率1%(1/92),3级神经事件发生率4%(4/92),无4级或5级事件。
- 标准治疗组1例治疗相关死亡(脓毒症);liso-cel组无治疗相关死亡。
- liso-cel组3级及以上长时间细胞减少发生率43%(40/92),标准治疗组为3%(3/91)。
研究设计与关键结果
- TRANSFORM为全球、开放标签、随机、三期试验,在美国、欧洲和日本47个中心开展;2018年10月23日至2020年12月8日筛查232例,184例随机分配至liso-cel组(n=92)或标准治疗组(n=92)。
- 中期分析数据截止2021年3月8日,中位随访6.2个月(IQR 4.4-11.5)。
- 主要终点无事件生存期:liso-cel组中位10.1个月(95%CI 6.1-未达到),标准治疗组2.3个月(95%CI 2.2-4.3),分层HR 0.35(95%CI 0.23-0.53),分层Cox比例风险模型单侧p<0.0001。
- 3级及以上不良事件:中性粒细胞减少liso-cel组80%(74/92)vs标准治疗组51%(46/91);贫血两组均49%(45/92 vs 45/91);血小板减少49%(45/92)vs 64%(58/91);长时间细胞减少43%(40/92)vs 3%(3/91)。
- 严重治疗中出现的不良事件:liso-cel组48%(44/92),标准治疗组48%(44/91)。
- liso-cel二线治疗未发现新的安全性问题;liso-cel组无治疗相关死亡,标准治疗组1例治疗相关死亡(脓毒症)。
证据类型、等级与局限
- 证据类型:开放标签、随机、三期试验(TRANSFORM)的预设中期分析。
- 疗效按意向治疗人群(所有随机分配患者)评估,安全性在接受了任何治疗的患者中评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些结果支持liso-cel作为早期复发或难治性LBCL新的二线治疗推荐。
- 适用人群为原发难治或对初始治疗有反应后≤12个月内复发、ECOG≤1、适合自体HSCT的18-75岁LBCL成人患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Patients with large B-cell lymphoma (LBCL) primary refractory to or relapsed within 12 months of first-line therapy are at high risk for poor outcomes with current standard of care, platinum-based salvage immunochemotherapy and autologous haematopoietic stem cell transplantation (HSCT). Lisocabtagene maraleucel (liso-cel), an autologous, CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has previously demonstrated efficacy and manageable safety in third-line or later LBCL. In this Article, we report a prespecified interim analysis of liso-cel versus standard of care as second-line treatment for primary refractory or early relapsed (within 12 months after response to initial therapy) LBCL.
METHODS: TRANSFORM is a global, phase 3 study, conducted in 47 sites in the USA, Europe, and Japan, comparing liso-cel with standard of care as second-line therapy in patients with primary refractory or early (≤12 months) relapsed LBCL. Adults aged 18-75 years, Eastern Cooperative Oncology Group performance status score of 1 or less, adequate organ function, PET-positive disease per Lugano 2014 criteria, and candidates for autologous HSCT were randomly assigned (1:1), by use of interactive response technology, to liso-cel (100 × 106 CAR+ T cells intravenously) or standard of care. Standard of care consisted of three cycles of salvage immunochemotherapy delivered intravenously-R-DHAP (rituximab 375 mg/m2 on day 1, dexamethasone 40 mg on days 1-4, two infusions of cytarabine 2000 mg/m2 on day 2, and cisplatin 100 mg/m2 on day 1), R-ICE (rituximab 375 mg/m2 on day 1, ifosfamide 5000 mg/m2 on day 2, etoposide 100 mg/m2 on days 1-3, and carboplatin area under the curve 5 [maximum dose of 800 mg] on day 2), or R-GDP (rituximab 375 mg/m2 on day 1, dexamethasone 40 mg on days 1-4, gemcitabine 1000 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1)-followed by high-dose chemotherapy and autologous HSCT in responders. Primary endpoint was event-free survival, with response assessments by an independent review committee per Lugano 2014 criteria. Efficacy was assessed per intention-to-treat (ie, all randomly assigned patients) and safety in patients who received any treatment. This trial is registered with ClinicalTrials.gov, NCT03575351, and is ongoing.
FINDINGS: Between Oct 23, 2018, and Dec 8, 2020, 232 patients were screened and 184 were assigned to the liso-cel (n=92) or standard of care (n=92) groups. At the data cutoff for this interim analysis, March 8, 2021, the median follow-up was 6·2 months (IQR 4·4-11·5). Median event-free survival was significantly improved in the liso-cel group (10·1 months [95% CI 6·1-not reached]) compared with the standard-of-care group (2·3 months [2·2-4·3]; stratified hazard ratio 0·35; 95% CI 0·23-0·53; stratified Cox proportional hazards model one-sided p<0·0001). The most common grade 3 or worse adverse events were neutropenia (74 [80%] of 92 patients in the liso-cel group vs 46 [51%] of 91 patients in the standard-of-care group), anaemia (45 [49%] vs 45 [49%]), thrombocytopenia (45 [49%] vs 58 [64%]), and prolonged cytopenia (40 [43%] vs three [3%]). Grade 3 cytokine release syndrome and neurological events, which are associated with CAR T-cell therapy, occurred in one (1%) and four (4%) of 92 patients in the liso-cel group, respectively (no grade 4 or 5 events). Serious treatment-emergent adverse events were reported in 44 (48%) patients in the liso-cel group and 44 (48%) in the standard-of-care group. No new liso-cel safety concerns were identified in the second-line setting. There were no treatment-related deaths in the liso-cel group and one treatment-related death due to sepsis in the standard-of-care group.
INTERPRETATION: These results support liso-cel as a new second-line treatment recommendation in patients with early relapsed or refractory LBCL.
FUNDING: Celgene, a Bristol-Myers Squibb Company.
参考来源
- Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022. PMID: 35717989. doi:10.1016/S0140-6736(22)00662-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。